Provided by Tiger Trade Technology Pte. Ltd.

Neurosense Therapeutics Ltd

0.3763
+0.02597.39%
Post-market: 0.3761-0.0002-0.05%19:30 EDT
Volume:128.46K
Turnover:47.28K
Market Cap:14.21M
PE:-0.86
High:0.3900
Open:0.3630
Low:0.3512
Close:0.3504
52wk High:1.98
52wk Low:0.2500
Shares:37.77M
Float Shares:25.85M
Volume Ratio:0.24
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4366
EPS(LYR):-0.4366
ROE:-2174.98%
ROA:-247.30%
PB:-9.11
PE(LYR):-0.86

Loading ...

Neurosense Therapeutics - Granted South Korean Patent Covering Primec Composition for ALS

THOMSON REUTERS
·
Jun 11

NeuroSense wins South Korean patent for PrimeC ALS drug composition through 2042

Reuters
·
Jun 11

Roth MKM Keeps Their Buy Rating on Neurosense Therapeutics Ltd. (NRSN)

TIPRANKS
·
Jun 10

NeuroSense secures Japan patent for PrimeC ALS drug formulation through 2042

Reuters
·
Jun 09

NeuroSense meets Health Canada on PrimeC regulatory pathway for ALS drug submission

Reuters
·
Jun 08

NeuroSense prices $600,000 private placement at $0.8 per share

Reuters
·
Apr 29

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)

TIPRANKS
·
Apr 27

NeuroSense announces departure of Chief Medical Officer

TIPRANKS
·
Apr 27

NeuroSense CMO Ferenc Tracik steps down, effective April 27

Reuters
·
Apr 24

NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042

Reuters
·
Apr 06

NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement

Reuters
·
Apr 03

Neurosense Therapeutics Ltd. (NRSN) Receives a Buy from Roth MKM

TIPRANKS
·
Apr 02

NeuroSense files Form 3 as CFO Or Eisenberg reports beneficial ownership

Reuters
·
Apr 02

NeuroSense FY25 net loss widens 9% to USD 11.1 million

Reuters
·
Apr 01

NeuroSense Therapeutics director Revital Mandil-Levin files initial beneficial ownership statement

Reuters
·
Apr 01

Israel's NeuroSense Therapeutics 2025 net loss widens as expenses rise

Reuters
·
Mar 31

BRIEF-NeuroSense Therapeutics FY EPS USD -0.44

Reuters
·
Mar 31

Neurosense Therapeutics FY Operating Income USD -11.085 Million

THOMSON REUTERS
·
Mar 31

Neurosense Therapeutics FY EPS USD -0.44

THOMSON REUTERS
·
Mar 31

Press Release: NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 31